WebJan 9, 2024 · CHRS has a market cap of $777mn and a cash reserve of $286mn. In November, Coherus revised the guidance range of combined 2024 R&D and SG&A expenses from $375 - $395 million to a range of … Web18 hours ago · The Price to Free Cash Flow ratio or P/FCF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator ...
Coherus: Biosimilar Specialist With Approval Shot For Cancer Drug ...
WebJun 18, 2024 · CHRS has a market cap of $1.08bn and a cash balance of $399mn. Last year, the company had nearly half a billion dollar in product revenue. Bottom line The standard gripe of investors with CHRS... WebApr 9, 2024 · The company has a market capitalization of $609.81 million, a PE ratio of -2.04 and a beta of 0.95. Coherus BioSciences, Inc. has a 52-week low of $5.58 and a 52-week high of $14.11. undefinedceoofdreamnotfound
Sutro Biopharma (NASDAQ:STRO) vs. Coherus BioSciences …
WebDec 20, 2024 · Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta® in the United States, and expects to launch the FDA-approved Humira® biosimilar YUSIMRY™ (adalimumab-aqvh) in the ... WebMar 28, 2024 · The Coherus BioSciences stock price gained 7.00% on the last trading day (Tuesday, 28th Mar 2024), rising from $6.00 to $6.42.During the last trading day the stock fluctuated 4.30% from a day low at $6.28 to a day high of $6.55.The price has risen in 5 of the last 10 days and is up by 1.1% over the past 2 weeks. Volume has increased on the … Web2 days ago · Get a real-time Coherus BioSciences, Inc. (CHRS) stock price quote with breaking news, financials, statistics, charts and more. ... Market Cap: 620.96M: Revenue (ttm) 211.04M: Net Income (ttm)-291.75M: Shares Out ... 3, 2024: About CHRS. Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno … undefeated quarterback training